Description

Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma[1][2].–80°C, protect from light-Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Nikoleta Sachini, et al. Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma. Blood. 2021.|[2]Zammarchi F, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018 Mar 8;131(10):1094-1105.-CASNumber-1879918-31-6-MolecularWeight-147000 (average)-Compound Purity-99.37-SMILES-[Loncastuximab tesirine]-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Antibody-Drug Conjugates (ADCs);Apoptosis-Isoform–Pathway-Antibody-drug Conjugate/ADC Related;Apoptosis-MCE Product type-ADC Related